Expert Interview
Looking at Pfizer's EV-303 Study of PADCEV Plus KEYTRUDA in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
Ticker(s): PFE, MRK, ALPMFInstitution: Stony Brook Medicine
- Urologist and urologic oncologist at Stony Brook for 25 years
- Specializes in areas including the prevention of BPH as well as managing bladder and prostate cancer
- Manages 100-125 patients with bladder cancer
Describe your background and practice setting
Added By: nick_adminHow many patients with bladder cancer do you currently manage?
Added By: nick_adminCan you describe the standard of care for bladder cancer?
Added By: nick_adminWhere would this combination therapy fit into your treatment algorithm for bladder cancer?
Added By: nick_adminRate your excitement for this combination therapy on a scale of 1-10
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
